NEWSROOM

Healthcare

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Sep 4, 2024

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and...

SS Innovations International, Inc. Announces First Mantra Surgical Robotic System Sale in South America

SS Innovations International, Inc. Announces First Mantra Surgical Robotic System Sale in South America

Sep 3, 2024

SS Innovations receives Regulatory Approval for Clinical Use in Ecuador SS Innovations Partners with Medical Device Firm Ingemedica S.A. for Distribution in Ecuador The first SSi Mantra Surgical Robotic System to be installed at Interhospital, Guayaquil City, Ecuador Fort Lauderdale, FL., September 3, 2024 - SS Innovations International, Inc. (the Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery...

SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock

SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock

Aug 30, 2024

Fort Lauderdale, FL., August 30, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today issued an update to its shareholders and the investment community on the status of its audit process and the trading market for its common stock. As previously reported in its Securities and Exchange...

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

Aug 29, 2024

Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, will present at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9th through 11th in New York City at the Lotte Palace Hotel....

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Aug 27, 2024

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual...

Halberd Corp. Issues Letter to Shareholders

Halberd Corp. Issues Letter to Shareholders

Aug 26, 2024

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Aug 26, 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Aug 22, 2024

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory...

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers

Aug 21, 2024

Study supports BioStem’s strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the benefits of Vendaje POMPANO BEACH, FL, August 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the Institutional Review Board (IRB) has approved a clinical study to evaluate Vendaje® for...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)

Aug 21, 2024

New York, NY. August 21, 2024 - ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke(“TTS”)regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Aug 15, 2024

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. New York, NY, August 15, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging and age-related diseases; today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human...

American Shared Hospital Services Announces Second Quarter 2024 Earnings Conference Call

American Shared Hospital Services Announces Second Quarter 2024 Earnings Conference Call

Aug 14, 2024

Call Scheduled for Today at 6:30 PM ET SAN FRANCISCO, August 14, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its second quarter 2024 financial results today, August 14th at 6:30 pm ET / 3:30 pm PT. The second quarter 2024 financial results press release...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Aug 12, 2024

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during...

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

Aug 12, 2024

Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5% sequential revenue increase compared to Q1 2024 Achieves second consecutive quarter of positive net income with $6.3 million Generated Adjusted Q2 2024 EBITDA of $10.0 million Financial Results Conference Call and Webcast on Monday, August 12, 2024, at 4:30 pm EDT POMPANO...

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Aug 12, 2024

Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

Aug 8, 2024

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders, We are thrilled to report that we have successfully launched GraftAssureTM, which is our research-use-only assay that can detect...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS

Aug 8, 2024

Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases New York, NY, August 8, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the...

REMSleep Holdings Inc. Issues Shareholder Letter

REMSleep Holdings Inc. Issues Shareholder Letter

Aug 6, 2024

Company Unveils Internal Corporate Goal of Capturing 10% of the CPAP Mask Market Within 24 Months CLEARWATER, Fla., August 6, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, published the following letter to shareholders. Dear REMSleep Shareholders and Interested Investors: Our company’s primary focus is two-fold. First, we are dedicated to providing high-quality products and experiences for CPAP therapy to support our customers and their families....

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte Announces August Investor Conferences Participation

Aug 5, 2024

IRVINE, Calif., August 5, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors. Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14,...

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Aug 5, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., August 5, 2024, — BioStem Technologies, Inc. (OTC: BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the market close on Monday, August 12, 2024. The company will also host a conference call and webcast at 4:30 PM ET to discuss the...

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Aug 1, 2024

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62 per share (or...

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Aug 1, 2024

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Aug 1, 2024 - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples

Jul 24, 2024

Clearwater, FL, July 24, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, is thrilled to announce that a significant distributor in the CPAP industry has requested samples of its new nasal interface, the DELTAWAVE Nasal Pillows System. This request marks a pivotal step in REMSleep's mission to revolutionize sleep apnea treatment with cutting-edge technology and superior comfort. REMSleep is currently in the process of preparing the DELTAWAVE Nasal...

SinglePoint CEO Issues Update to Shareholders Highlighting Key Operational Milestones

SinglePoint CEO Issues Update to Shareholders Highlighting Key Operational Milestones

Jul 24, 2024

Revenue up 20% YoY as subsidiary Boston Solar continues to grow PHOENIX, Arizona, July 24, 2024 -- SinglePoint Inc. (CBOE: SING), a leading provider in the renewable energy sector, issues an update to shareholders from CEO Wil Ralston highlighting key operational milestones: Dear Follow Shareholders, The Company continues to refine and strengthen operations as reflected in our recently filed annual financial statement (10K) for the year ended December 31, 2023. In particular, management...

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Jul 24, 2024

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-AxTM nasal spray in...

REMSleep Holdings Inc. Issues Shareholder Letter

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System

Jul 17, 2024

Clearwater, FL, July 17, 2024– REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions, is thrilled to announce a comprehensive marketing strategy for its revolutionary DELTAWAVE Nasal Pillows System. This strategic plan aims to significantly expand the market presence of DELTAWAVE by identifying and partnering with key distributors nationwide The DELTAWAVE Nasal Pillows System, designed with cutting-edge technology, offers an innovative solution for those suffering...

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 15, 2024

NEW YORK, N.Y., July 15, 2024 – PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's (Nasdaq: SNGX) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte™ (synthetic hypericin) is a novel photodynamic therapy for the treatment of early-stage cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma with no FDA-approved first-line treatments. Highlights from the Q&A:...

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

Jul 11, 2024

HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, "Take Advantage of the Moment." In this episode, Riggs highlights Oncocyte's innovative strategies in molecular diagnostic technology and the significant impact of this technology on patient care. Hosted by Tom Hickey, a partner at Excelerant Consulting and a seasoned expert in medical device...

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

Jul 10, 2024

POMPANO BEACH, FL, July 10, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ulcers are a...

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

Jul 9, 2024

JV will Establish Company’s 4th International Center SAN FRANCISCO, CA, July 9, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that it has signed a joint venture agreement to partner in a Gamma Knife treatment facility in Guadalajara, Mexico. AMS has signed a Joint Venture (“JV”) agreement with Hospital San...